Phase 2
Completed N=43
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
Source: ClinicalTrials.gov NCT00509067 ↗Enrolled (actual)
43
Serious AEs
2.3%
Results posted
Feb 2014
Primary outcomePrimary: Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS) — 17.63; 18.29; 17.06; 17.08 units on a scale
Summary
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS) |
17.63; 18.29; 17.06; 17.08; 13.93; 17.26 | — |
| SECONDARY Clinical Global Impression |
4.32; 4.38; 4; 3.92; 3.67; 4.04 | 0.93 |
| SECONDARY MATRICS Verbal Learning and Memory |
20.5; 20.6; 21.8; 21.2; 23.0; 20.4 | 0.23 |
Eligibility Criteria
Inclusion Criteria
- Meets DSM-IV criteria for schizophrenia or schizoaffective disorder
- Eligible for care within the Veterans Affairs Medical system
- Taking risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole (oral or injection)
Exclusion Criteria
- Significant liver, kidney, lung, endocrine, active peptic ulcer, or cardiovascular disease
- Seizure disorder and/or head injury
- Substance use or abuse within 3 months of study entry
- Pregnant
Data sourced from ClinicalTrials.gov (NCT00509067). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.